Here is the latest stock price and chart of WALPAR NUTRITIONS LTD.. For more details, see the WALPAR NUTRITIONS LTD. company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Revealing Soon: A Potential Huge Investing Opportunity for Investors
Live BSE Quotes |
---|
Not listed |
Live NSE Quotes | May 22, 2024 (Close) | ||
---|---|---|---|
Price (Rs)114.45 | Open (Rs) 114.45 | High (Rs) 114.45 | Low (Rs) 114.45 |
% Change5.00 | Volume 1,000 | Value (Rs) 114,450 | 52-Week H/L 153.95 / 72.30 |
BSE Sensex | CNX Nifty |
As of March 2024, company promoters held 71.23% stake in , with no shares having been pledged. To know more, check out the latest shareholding pattern of .
Before you go, here's an alert on you may want to take note of...
Date | Announcement | Ex-Date |
---|---|---|
27-May-2024 | Quarterly Results | - |
List of All Upcoming Corporate Actions
On the NSE, WALPAR NUTRITIONS LTD. last traded price was up 5.0% at Rs 114.5.
For the financial year 2023, WALPAR NUTRITIONS LTD. declared dividend amounting to Rs 0.0 per share. At the current price of Rs 114.5, this results in a dividend yield of 0.0%.
Based on marketcap, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks ranked by marketcap here.
Also, here's one of our more popular screens related to marketcap: India's Biggest Companies by Marketcap.
Based on sales, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
Curious to know which Indian companies are growing their sales at a faster rate than their peers? Check out India's Fastest Growing Companies by Sales.
Based on net profit, these are the top pharmaceuticals companies in India:
You can see the full list of pharmaceuticals stocks.
In case you are wondering which company logs in the biggest net profit margin in India, check this out: High Profit Margin Companies in India.
Indian share turned positive as the session progressed and ended the day higher.